BIOA

The past six months saw significant volatility for BioAge Labs' stock, trading between a 52-week high of $25.96 and a low of $5.04. In February 2026, BioAge completed an upsized public offering, raising $132.3 million. March 2026 brought positive interim Phase 1 data for BGE-102, showing potential reductions in inflammatory biomarkers. In July 2026, the stock plunged over 50% after Novo Nordisk's anti-inflammatory drug ziltivekimab failed its Phase 3 trial, raising concerns about similar inflammation pathways. September 2026 saw the first participant dosed in QUELL-DME, a Phase 2 trial for BGE-102 in diabetic macular edema, and the start of a Phase 2 dose-ranging trial for BGE-102 in cardiovascular risk. Recent analyst activity includes Wall Street Zen downgrading BioAge Labs to a "strong sell" in October 2026 and Needham & Company LLC reducing its price target from $50.00 to $35.00 in July 2026, despite a general "Moderate Buy" or "Strong Buy" consensus.